NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Sponsor: BioPorto Diagnostics
Listed as NCT02121470, this observational or N/A phase trial focuses on Acute Kidney Injury and remains completed. Sponsored by BioPorto Diagnostics, it has been updated 11 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioPorto Diagnostics
For direct contact, visit the study record on ClinicalTrials.gov .